9 results about "Flumazenil" patented technology

The invention relates to the technical field of organic synthesis, and particularly discloses a synthesis method of a flumazenil EP impurity B. The synthesis method comprises the following steps: step 1, reacting a compound 1 as shown in a formula (11) with a compound 2 as shown in a formula (12) at 50-130 DEG C for 8-24 hours; separating and purifying the reaction liquid to obtain a compound 3; 2, carrying out a free radical bromination reaction on the compound 3 in an inert gas environment to obtain a compound 4; step 3, the compound 4 and methylamine are subjected to a heating reaction in an inert gas environment, and a compound 5 is obtained; and 4, heating the compound 5 and bis-pinacol borate in an inert gas environment to react to obtain a compound 6, and oxidizing to obtain a compound 7. A catalyst, a reagent and the like in the method are easy to obtain and low in toxicity, and the yield of the obtained compound 7 is high.

1. Name of the Design Product: Packaging Box (Flumazenil Injection). 2. Use of the Design Product: Packaging box for containing medicines. 3. Design Key Points of the Design Product: The combination of shape and pattern. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective view.

Provided herein are formulations and methods for reversing incapacitation from intentional poisoning, and can include administering to a subject one or more fast-degrading unit dosage forms or nasal sprays, wherein the fast-degrading unit dosage forms and the nasal sprays comprise flumazenil. The unit dosage forms can be selected from the group consisting of a dissolving lozenge, a lollipop, a sublingual film, and a buccal tablet, and can comprise about 0.2 mg to about 2 mg of flumazenil, and the sublingual film can degrade in the mouth in about 3 to about 6 minutes.

The invention relates to the technical field of medicine quality control and separation detection, in particular to a flumazenil injection related substance detection method and application thereof. Taking the test solution and the contrast solution, and carrying out quantitative detection on the impurity A, the impurity B, the impurity D, the impurity E and the impurity F by adopting a liquid chromatography self-contrast method; the chromatographic conditions are as follows: a phenyl-hexyl mixed bonded phase chromatographic column is adopted, the column temperature is 15 DEG C, and the number of theoretical plates is gt; 15000, 15000; the mobile phase is acetonitrile and diammonium hydrogen phosphate (0.02 M, pH 4.8), the gradient elution is carried out for 0-10 minutes, and the acetonitrile accounts for 5%-25%; 25% of acetonitrile is used for 10-35 min; the detection wavelength is 230nm. In order to eliminate co-elution interference, a dual-wavelength combined detection technology is adopted, and interference of impurity peaks on main peaks is further eliminated. The methodology verifies that the detection method can be used for detecting related substances in flumazenil injection and bulk drugs.

There is disclosed a method for treating post-traumatic stress disorder (PTSD) or treating anxiety comprising administering flumazenil. The flumazenil may be administered non-orally and / or at least daily. The non-oral route of administration may be subcutaneous, buccal, sublingual, nasal, transdermal, intravenous, intramuscular injection, or rectal. The present disclosure further provides a flumazenil dosage form comprising (a) a buccal flumazenil lozenge formulation; (b) a flumazenil dissolving sublingual strip formulation; (c) a subcutaneous injection dosage form of an aqueous solution of flumazenil; or (d) a rectal suppository formulation, wherein each flumazenil dosage form is capable of systemically delivering from about 0.1 mg to about 3 mg of flumazenil. There is further disclosed a chronic (at least one week or longer) treatment regimen of flumazenil to reach the brain of a patient having anxiety or PTSD, comprising administering a daily non-oral dose of flumazenil.

A < 11 > C radiopharmaceutical synthesis system relates to the technical field of radiopharmaceutical synthesis, and adopts the technical scheme that the < 11 > C radiopharmaceutical synthesis system comprises a primary reaction module, a first three-way valve group, an online conversion module, a secondary reaction module, a liquid phase purification module, a solid phase extraction module, a column purification module and a pipetting module. Five < 11 > C-radiopharmaceuticals can be synthesized and comprise sodium acetate, choline, methionine, rachlopride and flumazenil, the sodium acetate, the choline and the methionine are column purification drugs, and the rachlopride and the flumazenil are liquid phase purification drugs; the system also has the functions of pipeline blockage inspection and leakage inspection, and stable operation of the system is guaranteed; except for the injection pump, the capturing column, the infusion pump and the sucking pump, most of pipelines and components are arranged on the upper surface of the mounting panel, and a plurality of three-way valves are integrated into two three-way valve groups, so that the pipelines between two-time synthesis are convenient to replace.

The present application relates to compositions comprising flumazenil and naltrexone and methods of use thereof. In particular, the present invention relates to a pharmaceutical composition comprising a microdose of flumazenil and a microdose of naltrexone, or a pharmaceutically acceptable salt thereof, where the flumazenil and naltrexone are present in a weight ratio of about 25: 1 to about 10: 1, where the composition is in the form of a single dose unit, and wherein the single dose unit comprises flumazenil in an amount that provides a daily microdose in the range of about 250 to about 7,500 micrograms and naltrexone in an amount that provides a daily microdose in the range of about 25 to about 1,000 micrograms. The present invention also relates to methods of treating depression and / or anxiety and / or post traumatic stress disorder (PTSD) using a combination of flumazenil and naltrexone.

Provided herein are formulations and methods for reversing an attempted poisoning incapacitation and may comprise administering to a subject one or more rapidly degrading unit dosage forms or a nasal spray, wherein the rapidly degrading unit dosage forms and the nasal spray comprise flumazenil. The unit dosage forms may be selected from the group consisting of a dissolving lozenge, lollipop, sublingual film, and buccal tablet and may comprise from about 0.2 to about 2 mg flumazenil and the sublingual film may degrade in the mouth over about 3 to about 6 minutes.

The present invention relates to pharmaceutical compositions comprising flumazenil and naltrexone, especially compositions comprising low-dose flumazenil and low-dose naltrexone. The present invention also relates to methods for the use of a combination of flumazenil and naltrexone in the treatment of depression and / or anxiety and / or post-traumatic stress disorder (PTSD).